EKO / TSX Venture Exchange
MONTREAL, Feb. 6 /CNW Telbec/ - Noveko International Inc. ("Noveko" or
the "Company") announces that its subsidiary Laboratoire SyMa Inc. ("SyMa")
has signed an exclusive agreement with Magnum Pharmaceutics Inc. ("Magnum"), a
management services company specializing in the commercialization of
pharmaceutical and related products with operations in Canada and worldwide.
This agreement will allow the marketing of Azuro(TM) brand products throughout
the Canadian pharmacy market with the support of Magnum's services, primarily
in sales and distribution.
SyMa manufactures the Azuro(TM) sanitizers - antimicrobial products for
hands, feet and surfaces, available in various formats for consumers and
healthcare professionals. Distributed in Quebec for slightly over two years,
Azuro(TM) products are targeted to pharmacies, retail outlets and the
corporate, governmental and healthcare sectors, and are also available under
private labels for corporate gifts, fund-raising, golf tournaments, etc. In
2007, SyMa received a DIN (Drug Identification Number) from Health Canada,
authorizing it to sell its products in healthcare institutions, and FDA
authorization to market its products in the United States.
"Building on the success the Azuro(TM) brand has already enjoyed in
Quebec, we are pleased to join with Magnum, whose national services will
enable us to enter the Canadian pharmacy market through drugstores, mass
merchandise and 'food-with-pharmacy' outlets" said Marc Demers, President of
SyMa. "Magnum offers a national network that contacts our valuable retail
partners in every region of the country. We will start to see the benefits of
this agreement in the first months of 2008 and anticipate sustained sales
growth for years to come, including the introduction of new Azuro(TM) products
later this year."
Brent Pearce, Director of Marketing at Magnum, added "we are enthusiastic
about the opportunity to work with dynamic companies such as Noveko and its
subsidiaries on both Azuro(TM) and other initiatives that are presently in
Noveko International Inc. currently has four subsidiaries: S.A.S. ECM,
Noveko Inc., Laboratoire SyMa Inc. ("SyMa") and Bolduc Leroux Inc. ("BLI").
ECM specializes in the design and marketing of portable real-time ultrasound
scanners for use in veterinary and human medicine. Noveko Inc. develops the
Company's biomedical and environmental business, specifically its patented
antimicrobial filtration technology and derivative products (Noveko(TM)
antimicrobial face masks and air filters). SyMa specializes in the manufacture
of sanitizers, more specifically the antimicrobial products (for hands, feet
and surfaces) sold under the Azuro(TM) trademark. For its part, BLI
specializes in the custom processing and distribution of steel products based
on client specifications and designs. It has also developed and markets a line
of downdraft particle extraction tables for various markets. Operating since
September 2002, the Company was listed on the TSX Venture Exchange on
February 3, 2004.
The information set forth in this press release includes certain
forward-looking statements. Such statements are based on assumptions exposed
to major risks and uncertainties. Although Noveko deems the expectations
reflected in these forward-looking statements to be reasonable, the Company
cannot provide any guarantee as to the materialization of the expectations
reflected in these forward-looking statements. The TSX Venture Exchange has
not reviewed and does not accept responsibility for the adequacy or accuracy
of this release.
For further information:
For further information: André Leroux, Chairman of the Board and Chief
Executive Officer; Alain Bolduc, President and Chief Operating Officer, Noveko
International Inc., (514) 344-3030, http://www.noveko.com